MON-608 The Impact of Continuous Glucose Monitor Use on Diabetes Self-Management Behaviors in Adults: A Pilot Study in an Endocrine Specialty Clinic

Abstract Disclosure: K.M. St. Jean: None. P. Underwood: None. N. Patel: None. R. Franca: None. J.N. Keels: None. R. Rick Longo: None. J. Upadhyay: None. Introduction: Continuous glucose monitor (CGM) use improves diabetes (DM) clinical outcomes (lower hemoglobin A1c (A1c), reduced hypoglycemia) in Adults with DM prescribed insulin. The mechanisms underlying this relationship are unknown, but may relate to the influence of CGM use on diabetes self-management behavior (DMB). Methodology: A pilot-randomized control trial (RCT) was conducted on 30 patients (16 libre-professional CGM (user blind) and 14libre 2 CGM). Adults (18-80y) with an ICD-10 diagnosis of DM within the past 12 months, hemoglobin A1c (A1c >8%) measured within the past 6 months, stable weight within the past 3 months (BMI ± 2 units were included.. All participants were given information on CGM use and general diabetes self-management education (DSME). DMB was measured using the Diabetes Self Care Inventory-Revised scale at visit 1 (baseline), visit 2 (2 weeks). Additional outcome variables, including Diabetes Distress, sleep quality, exercise habits, and nutrition, were obtained. Provider satisfaction with patient CGM use was also evaluated using a newly developed provider satisfaction survey. Results: Personal-CGM use supports improved diabetes self-care and decrease rates of hypoglycemia. Individuals using the freestyle libre 2 CGM had significantly lower rates of hypoglycemia (% glucose time <80-60mg/dl mean± standard deviation (SD) User Blind CGM: 1.92±3.92 vs Libre 2 0.14±0.36 p<0.0001), % glucose <60mg/dl) User Blind CGM: 0.92±2.15 vs. Libre 2 0±0 p<0.0001). Libre 2 CGM users had significantly lower levels of anger and fear (User Blind CGM: 2.0±1.55 vs Libre 2 1.7±0.72 p=0.01) and lower levels of failing in their diabetes routine compared to User-blind CGM users as measured by the Diabetes Distress Scale (User Blind CGM: 2.81±1.74 vs Libre 2 2.42±1.94 p=0.04). Libre 2 CGM users also had significantly higher confidence in how exercise influences their glucose level compared to User-blind CGM users as measured by the DPP Diabetes Knowledge scale (User Blind CGM: 8.09±2.6 vs Libre 2 8.92±0.9 p=0.02). Further, 100% of the providers felt that CGM use by their patients was very effective and helped their clinical decision-making during the visit. Providers did not feel that reviewing CGM data prolonged their visit. Conclusion: This pilot RCT suggests that personal CGM use decreases rates of hypoglycemia, lowers diabetes distress, and improves some aspects of diabetes self-management behavior in adults with diabetes seen in an endocrine clinic. This data reaffirms that CGM use in patients with poorly controlled diabetes is associated with improved DM clinical outcomes and supports endocrine provider clinical decision making. Presentation: Monday, July 14, 2025